Biohealth Innovation
GlycoMimetics, Inc. (NASDAQ: GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat rare diseases, announced today that the Japan Patent Office (JPO) has issued Patent No. 6366150, for uproleselan (GMI-1271). The newly issued patent covers uproleselan’s composition of matter as well as pharmaceutical formulations, and expires in December 2032.
Popper and Co., a strategy consulting and transaction advisory firm serving the needs of the medical technology and life sciences industries, announced today that Co-Founder and President Caroline Popper, M.D., will speak at the 10th Annual Next Generation Dx Summit on August 22 at 5 pm ET at the Grand Hyatt Washington in Washington, DC.
Calling all pediatric cardiovascular devices $100K competition now accepting proposals
We are now accepting proposals for our annual pediatric medical device pitch competition! New this year, the competition is focused on pediatric cardiovascular devices – a significant unmet need for children. The competition will be held on Sunday, Sept. 23, 2018 in Philadelphia, Penn. at our 6th Annual Pediatric Device Innovation Symposium. The deadline to apply is Monday, Sept. 10. For additional competition details and to apply, click here.
The Emmes Corporation today announced that it was selected as one of the best places to work in the greater Washington area. The Washington Post’s 2017 Top Workplaces list ranked private, public, nonprofit and government agencies based on the highest engagement ratings from their employees. The Washington Post used Workplace Dynamics to conduct the survey, with 3,000 area companies invited to participate and 150 organizations selected as Top Workplaces. Emmes was ranked 15th out of 25 in the large company category and was one of only two biotechnology organizations to make the list.
RegenxBio Inc. (NASDAQ:RGNX) raised $175.5 million through the sale of 2.7 million shares at $65 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Raymond James.
Venture investor Krishna Yeshwant uses a healthy amount of skepticism when vetting potential companies to invest in. His favorite time to invest is when one of his partners at the fund is excited about a particular company, even if nobody else is.
To better understand one of the most heated U.S. policy debates, we created a tournament to judge which of these nations has the best health system: Canada, Britain, Singapore, Germany, Switzerland, France, Australia and the U.S.
In the first such clinical trial in the United States, physician-scientists with the University of Maryland School of Medicine (UMSOM) are investigating the use of MRI-guided focused ultrasound to open the blood-brain barrier. The trial will be conducted with patients undergoing brain cancer surgery at the University of Maryland Medical Center (UMMC).
Recently, ClearMask received $25,000 in grant funding from the National Science Foundation (NSF) to support ClearMask's commercialization efforts. The funding is part of the NSF's National Innovation Corps (I-Corps) program that helps scientists and engineers move their technologies toward commercialization.
In last week’s Amplified column, I discussed how the traditional wisdom that small business pursues disruptive innovation and big business pursues sustaining innovation may no longer hold. This is especially likely in industries consisting of only a few large players that both have the resources to engage in disruptive innovation themselves and to raise the costs of entry to would-be competitors.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for an all-cash consideration of $270 million. PaxVax is majority owned by an affiliate of Cerberus Capital Management, L.P.
Maryland’s health tech startup ecosystem is at it again. Silver Spring-based startup which is named as Aziyo Biologics Inc. has raised an amount of $10 million from seven leading investors in a funding round which has been disclosed yesterday night in SEC filings.
After a week of persistent rain throughout Maryland, it was blue skies and a perfect 85-degree summer afternoon that marked an important day for Paragon Bioservices and their 250+ employees. Dozens of those employees stepped off a charter bus from Baltimore to see the brand new 151,000 sq/ft GMP biomanufacturing facility near BWI for the first time. The wide-open parking lots and 200 yards between the nearest building presented a much different landscape than they were used to at their current UM BioPark location in the city. An afternoon picnic and site tour was organized as a celebration for their employees, who got to enjoy some delicious ole’ fashioned BBQ, music and games outside before a short welcome ceremony.
We want to offer you the best possible experience when using the OrganoPlate® for your experiments. This page contains training videos and protocols to get you started. For optimal user experience, we recommend you to follow these 5 steps before your first experiment:
Paragon Bioservices, the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, announces today two key leadership promotions. Deborah Wild has been promoted from Vice President, Quality, Validation and Regulatory Affairs to Senior Vice President, Quality, Validation and Regulatory Affairs, and Ruby Hofmann has been promoted from Vice President, Human Resources and Organizational Development to Senior Vice President, Human Resources, and Organizational Development.
Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the Eversense® CGM System is now available at trained clinics across the U.S. and physicians have begun sensor placements with patients. Concurrently, the company reported that its first commercial payer, Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey, has added coverage of the Eversense System to its Medical Policy.
Johns Hopkins University has been awarded up to $30 million to lead a consortium of three Mid-Atlantic universities that will work together on research projects with the National Institute of Standards and Technology.
Venture Capital - Generating Opportunity in Montgomery County
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that it has distributed to shareholders a mid-year update letter reviewing the company's recent progress and clinical plans for the remainder of 2018 and 2019.
Meet RESI’s Network of Global Investors and Channel Partners
This fall, the Redefining Early Stage Investments Conference (RESI) will expand to include tech hubs and companies from the First Coast: DC, MD, PA, NJ, NY, RI, CT, and MA. RESI invites earliest stage companies from the discovery stage through venture stage: companies seeking grants, seed, angel, series A, and series B funding.
As a client/partner of BioHealth Innovation and/or an early stage biohealth start-up in the BioHealth Capital Region, you can attend the RESI Boston September Conference at a reduced rate - $300 each ticket for the first 5 signups; each ticket valued at $1,295.
RESI is a partnering vehicle for you to connect with global investors and strategic partners. You'll have an opportunity to showcase your technology and assets in a poster board format with our table in the exhibit hall. You can participate in partnering and networking all day, and explore the exhibit hall, investor panels and entrepreneur workshops.
Email This email address is being protected from spambots. You need JavaScript enabled to view it. for the Discount Code and Register Now
$300 for Tech Hub Members Includes:
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced today that the first healthy subjects have been dosed in a Phase 1 clinical study of BT-11, a first-in-class, orally-administered, molecule targeting the LANCL2 pathway. The Phase 1 study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study intended to enroll up to 70 healthy volunteers to evaluate the safety and tolerability of BT-11. BT-11 is in development for treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD).
As a BARDA DRIVe Accelerator, the Center for Biotechnology is pleased to announce that the simplified funding application process, called EZ BAA, is now open. Medical product developers, research teams, and companies offering disruptive solutions to health security threats are invited to submit abstracts using this simplified EZ BAA process.
Applications accepted through this streamlined process must offer transformative innovation, products and technologies to protect Americans from health security threats. This application process is a business friendly simple abstract.
In-scope priority areas include products and solutions to reduce illness and death from sepsis as part of DRIVe’s Solving Sepsis initiative; technologies and processes to identify infections and exposures to biological and other health threats, as outlined in the Early Notification to Act, Control, and Treat (ENACT) initiative; and tools and techniques to mitigate the damages and loss of life associated with catastrophic events.
Thursday, Septmember 27, 20184:00-7:00 PM
Enjoy an evening with food, fun and lively conversation at Biotech and Beer. Meet old friends and new colleagues in the life science community. Complimentary admission for any bioscience company employees, and university students and researchers with advanced registration. All others may purchase tickets.
Amazon has been keeping 20 cities guessing about its plans for a $5 billion second headquarters, with sites in Northern Virginia, Washington, and Montgomery County in the mix.
Who are the leading angel investors startup entrepreneurs should be pitching right now? How do you connect with them?
Effective fundraising for startups isn’t about how many people and firms you can blast your opportunity out to. It’s about getting in front of the right investors, with a strong pitch deck. A recent DocSend survey shows successfully funded startups contacted an average of just 58 investors, made 40 meetings, and took just 12.5 weeks to close their funding round.
Fairfax health technology company Vibrent Health hosted Congressman Gerry Connolly (D-VA, 11th District) at the company’s new offices for a town hall style meeting today, to talk about digital health initiatives, health care access, immigration issues and other topics of interest to Vibrent’s 140 employees.
“Congressman Connolly understands the importance of integrating health data from various sources to promote the best outcomes for individuals and for public health,” said Vibrent Health Founder and CEO Praduman “PJ” Jain. “We are eager to work with our leaders in government to continue developing digital health technology that advances health research and empowers people to live healthier lives.”
The 2018 UEDA Awards of Excellence finalists have been chosen following an extremely close competition this year. Higher education institutions and organizations across North America submit nominations annually for innovative programs that focus on developing economic prosperity in their communities and beyond. A panel of university and economic development professionals have chosen 24 finalists from the group of nominated projects.
U.S. Senator Ben Cardin (D-Md.), Ranking Member of the U.S. Senate Committee on Small Business & Entrepreneurship, today announced several provisions in the 2019 National Defense Authorization Act (NDAA) specifically focused on supporting small businesses in Maryland and nationwide. The annual defense funding bill passed the Senate Wednesday.
On the morning of Wednesday, July 25th, the U.S. Congress Joint Economic Committee held a hearing titled The Innovation Economy, Entrepreneurship, and Barriers to Capital Access. The day’s discussion focused on various federal policies that could be pursued by Congress to increase avenues for financing innovative businesses and improve the ranking of the United States as an innovative economy.
The long wait for a White House science adviser is over. President Donald Trump announced today that he intends to nominate meteorologist Kelvin Droegemeier, a university administrator and former vice-chair of the governing board of the U.S. National Science Foundation (NSF), to be director of the White House Office of Science and Technology Policy (OSTP). The OSTP director traditionally, but not always, also holds the title of the president’s science adviser.
Baltimore-based Personal Genome Diagnostics (PGDx) recently received a designation from federal regulators that’s designed to help allow patients to get quicker access to new devices.
United Therapeutics Corp. said it has received Food and Drug Administration approval for an implantable pump for Remodulin, its flagship pulmonary arterial hypertension drug.
QIAGEN N.V. and Hamilton Robotics, a privately held leader in automation and liquid handling technology, today announced a new collaboration to improve processing of QIAGEN’s QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test through the integration of Hamilton’s Microlab® STAR™ automated liquid handling workstation into the QFT-Plus assay workflow. QIAGEN’s fourth-generation QuantiFERON-TB Gold Plus is the modern gold standard for latent tuberculosis (TB) detection.
Close proximity to a host research university — check. Sustainably designed and preferably LEED-certified buildings — check. A state-of-the-art telecom infrastructure — check. An office of commercialization — check. These used to define a cutting-edge and competitive research park. Not anymore. Today's "A list" parks, or districts, look more like towns, complete with transit, lodging, residential and retail. Besides those, the University of Maryland's Discovery District in College Park will soon have coworking space, thanks to a recent partnership among the university, global coworking provider WeWork and Chesapeake Realty Partners.
VIP MEDIA DAY is an opportunity for local, regional and national media outlets to get a first-ever exclusive look into the Virginia Tech Corporate Research Center (VTCRC), located in Blacksburg, VA, and adjacent to Virginia Tech.